| Dr Robert A Haines, MD | |
|
477 Congress St Ste 201, Portland, ME 04101-3406 | |
| (207) 773-7811 | |
| (207) 773-0663 |
| Full Name | Dr Robert A Haines |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 477 Congress St Ste 201, Portland, Maine |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063591352 | NPI | - | NPPES |
| RB7 | Other | ME | ANTHEM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 009432 (Maine) | Primary |
| Entity Name | Spurwink Services Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760507297 PECOS PAC ID: 7810026945 Enrollment ID: O20100527000272 |
News Archive
At the Alzheimer's Association 2010 International Conference (ICAD) July 10-14 in Honolulu, HI, Syntermed, Inc. launched NeuroQ™ version 3.5, a nuclear medicine quantitative software platform for analysis and image display of brain FDG-PET scans. NeuroQ can increase physician accuracy in diagnosing and differentiating the many types of dementia, compared to visual interpretation alone of FDG-PET.
On occasion, a virus may jump from one host species to another and adapt to the new host. Such cross-species transmission happens more often than expected, according to new research published in PLOS Pathogens, and it may play a much bigger role in virus evolution than previously thought.
Cephalon, Inc. today announced that it has filed a definitive Consent Revocation Statement with the Securities and Exchange Commission (SEC) urging shareholders to reject Valeant Pharmaceuticals International Inc.'s proposals to remove Cephalon's entire Board of Directors and replace them with nominees hand-picked by Valeant.
Accretive Health, Inc., a leading provider of services that help healthcare providers generate sustainable improvements in their operating margins and healthcare quality while also improving patient, physician and staff satisfaction, today announced the pricing of the public offering of 6,500,000 shares of its common stock at a price to the public of $23.50 per share.
Prostate cancer is a serious health concern in Georgia. According to the American Cancer Society, the state of Georgia ranks 11th in number of estimated deaths per capita from the disease. In an effort to raise awareness about prostate cancer and ensure more men commit to be informed and screened, several companies and media organizations have joined the Georgia Prostate Cancer Coalition in launching a pledge campaign.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert A Haines, MD 899 Riverside St, Portland, ME 04103-1070 Ph: (207) 871-1200 | Dr Robert A Haines, MD 477 Congress St Ste 201, Portland, ME 04101-3406 Ph: (207) 773-7811 |
News Archive
At the Alzheimer's Association 2010 International Conference (ICAD) July 10-14 in Honolulu, HI, Syntermed, Inc. launched NeuroQ™ version 3.5, a nuclear medicine quantitative software platform for analysis and image display of brain FDG-PET scans. NeuroQ can increase physician accuracy in diagnosing and differentiating the many types of dementia, compared to visual interpretation alone of FDG-PET.
On occasion, a virus may jump from one host species to another and adapt to the new host. Such cross-species transmission happens more often than expected, according to new research published in PLOS Pathogens, and it may play a much bigger role in virus evolution than previously thought.
Cephalon, Inc. today announced that it has filed a definitive Consent Revocation Statement with the Securities and Exchange Commission (SEC) urging shareholders to reject Valeant Pharmaceuticals International Inc.'s proposals to remove Cephalon's entire Board of Directors and replace them with nominees hand-picked by Valeant.
Accretive Health, Inc., a leading provider of services that help healthcare providers generate sustainable improvements in their operating margins and healthcare quality while also improving patient, physician and staff satisfaction, today announced the pricing of the public offering of 6,500,000 shares of its common stock at a price to the public of $23.50 per share.
Prostate cancer is a serious health concern in Georgia. According to the American Cancer Society, the state of Georgia ranks 11th in number of estimated deaths per capita from the disease. In an effort to raise awareness about prostate cancer and ensure more men commit to be informed and screened, several companies and media organizations have joined the Georgia Prostate Cancer Coalition in launching a pledge campaign.
› Verified 3 days ago
Dr. Robert Charles King, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2 Portland Sq Ste 201, Portland, ME 04101 Phone: 207-607-4022 Fax: 207-613-5048 | |
Dr. Barbara Jane Wood, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 121 Middle St, Suite 404, Portland, ME 04101 Phone: 207-772-8634 Fax: 207-772-1629 | |
Amy Wood, PSY D Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 57 Exchange St, Suite 403, Portland, ME 04101 Phone: 207-772-7542 Fax: 207-775-4454 | |
Dr. Jeremy Ashley Spiegel, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 63 Preble St, Portland, ME 04101 Phone: 207-822-0232 | |
Robert Toscano, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 165 Lancaster St, Portland, ME 04101 Phone: 207-874-1030 Fax: 207-874-1044 | |
Dr. Charles J. Mallo, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 216 Vaughan St, Portland, ME 04102 Phone: 207-662-2221 Fax: 207-810-2367 |